Previous 10 | Next 10 |
home / stock / smfrw / smfrw news
The following slide deck was published by Sema4 Holdings Corp. in conjunction with this event. For further details see: Sema4 Holdings (SMFR) Investor Presentation - Slideshow
SIOUX FALLS, S.D. and STAMFORD, Conn., June 01, 2022 (GLOBE NEWSWIRE) -- Avera Health , an integrated regional health care system that serves 300 locations across the Upper Midwest, and Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today...
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following investor conferences: Conference: Jefferies Healthcare Conf...
The following slide deck was published by Sema4 Holdings Corp. in conjunction with their 2022 Q1 earnings call. For further details see: Sema4 Holdings Corp. 2022 Q1 - Results - Earnings Call Presentation
Sema4 Holdings Corp. (SMFR) Q1 2022 Earnings Conference Call May 13, 2022 04:30 p.m. ET Company Representatives Katherine Stueland - Chief Executive Officer Eric Schadt - Founder, President and Chief R&D Officer Isaac Ro - Chief Financial Officer Joel Kaufman - Vice President of Finance a...
Total revenue of $53.9 million 1,300 basis points of sequential adjusted gross margin improvement Reaffirming full year 2022 pro forma revenue target New operating model and focus on efficiencies to reduce 2022 cash burn by an estimated $50 million, extending cas...
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the compensation committee of Sema4’s board of directors granted newly-hired employees ...
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx, joins Sema4 as CEO and will serve on Board of Directors Eric Schadt, fou...
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the first quarter of 2022 after the market close on Thursday, May 12, 2022. On the same d...
STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform, Centrellis ® , has earned Certified status for information security by the Heal...
News, Short Squeeze, Breakout and More Instantly...
Sema4 Holdings Corp. Warrant Company Name:
SMFRW Stock Symbol:
NASDAQ Market:
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...